Investors

Press Releases

 
Press Releases
  Date Title View
Jan 5, 2012
Watertown, MA – January 5, 2012 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics, today announced that L. Patrick “Pat” Gage, Ph.D., biopharmaceutical industry pioneer, has been appointed as the company’s Chairman of the Board. I...
Oct 20, 2011
Watertown, MA – October 20, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that executives fro...
Oct 19, 2011
Watertown, MA – October 19, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that National Insti...
Sep 15, 2011
Watertown, MA – September 15, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that President an...
Sep 13, 2011
Watertown, MA – September 13, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that data describ...
Jun 23, 2011
Watertown, MA – June 23, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that the company will ...
May 9, 2011
Watertown, MA - May 9, 2011 - Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results of several studies designed to support the continued advancement of its lead antibiotic, TP-434, a potent new broad-spectrum intravenous...
Apr 6, 2011
Watertown, MA – April 6, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that the Company will ...
Mar 30, 2011
Watertown, MA – March 30, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that the Company will...
Mar 3, 2011
Watertown, MA – March 3, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) gram-negative pathogens) today announced that the Company will ...
FirstPrevious
...
14
NextLast
= add release to Briefcase